Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical research ...

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...

Shares of NASDAQ ONVO opened at $0.44 on Wednesday. Organovo has a 12-month low of $0.32 and a 12-month high of $1.74. The company has a market cap of $6.77 million, a P/E ratio of -0.42 and a ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply ...

Short interest in Organovo Holdings Inc (NASDAQ:ONVO) increased during the last reporting period, rising from 32.50K to 39.07K. This put 0.26% of the company's publicly available shares short.

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...